Published in Viral Immunol on May 02, 2012
Structure and function of respiratory syncytial virus surface glycoproteins. Curr Top Microbiol Immunol (2013) 1.15
Novel antigens for RSV vaccines. Curr Opin Immunol (2015) 0.99
Gene sequence variability of the three surface proteins of human respiratory syncytial virus (HRSV) in Texas. PLoS One (2014) 0.89
Respiratory Syncytial Virus Uses CX3CR1 as a Receptor on Primary Human Airway Epithelial Cultures. PLoS Pathog (2015) 0.89
Nanoparticle vaccines encompassing the respiratory syncytial virus (RSV) G protein CX3C chemokine motif induce robust immunity protecting from challenge and disease. PLoS One (2013) 0.87
A respiratory syncytial virus (RSV) vaccine based on parainfluenza virus 5 (PIV5). Vaccine (2014) 0.86
CX3CR1 Is Expressed in Differentiated Human Ciliated Airway Cells and Co-Localizes with Respiratory Syncytial Virus on Cilia in a G Protein-Dependent Manner. PLoS One (2015) 0.86
Sendai virus as a backbone for vaccines against RSV and other human paramyxoviruses. Expert Rev Vaccines (2015) 0.80
Development of safe and effective RSV vaccine by modified CD4 epitope in G protein core fragment (Gcf). PLoS One (2014) 0.78
Respiratory Syncytial Virus (RSV) Modulation at the Virus-Host Interface Affects Immune Outcome and Disease Pathogenesis. Immune Netw (2013) 0.78
Affinity-purified respiratory syncytial virus antibodies from intravenous immunoglobulin exert potent antibody-dependent cellular cytotoxicity. PLoS One (2013) 0.77
Respiratory syncytial virus human experimental infection model: provenance, production, and sequence of low-passaged memphis-37 challenge virus. PLoS One (2014) 0.77
Universal vaccine against respiratory syncytial virus A and B subtypes. PLoS One (2017) 0.76
Layer-By-Layer Nanoparticle Vaccines Carrying the G Protein CX3C Motif Protect against RSV Infection and Disease. Vaccines (Basel) (2015) 0.75
Monoclonal Antibody against G Glycoprotein Increases Respiratory Syncytial Virus Clearance In Vivo and Prevents Vaccine-Enhanced Diseases. PLoS One (2017) 0.75
A novel influenza virus hemagglutinin-respiratory syncytial virus (RSV) fusion protein subunit vaccine against influenza and RSV. J Virol (2013) 0.75
Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med (2005) 9.47
Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child (1986) 7.39
Antigenic characterization of respiratory syncytial virus strains with monoclonal antibodies. J Infect Dis (1985) 5.91
Respiratory-syncytial-virus infections, reinfections and immunity. A prospective, longitudinal study in young children. N Engl J Med (1979) 5.44
Two distinct subtypes of human respiratory syncytial virus. J Gen Virol (1985) 5.19
TNF-mediated inflammatory disease. J Pathol (2008) 5.00
Recovery from infants with respiratory illness of a virus related to chimpanzee coryza agent (CCA). I. Isolation, properties and characterization. Am J Hyg (1957) 4.28
Nucleotide sequence of the G protein gene of human respiratory syncytial virus reveals an unusual type of viral membrane protein. Proc Natl Acad Sci U S A (1985) 3.93
Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants. J Infect Dis (2005) 3.79
Immunity to and frequency of reinfection with respiratory syncytial virus. J Infect Dis (1991) 3.27
Circulation patterns of genetically distinct group A and B strains of human respiratory syncytial virus in a community. J Gen Virol (1998) 3.06
Recovery of cytopathogenic agent from chimpanzees with coryza. Proc Soc Exp Biol Med (1956) 3.03
Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy. J Infect Dis (2000) 2.90
Demonstration that glycoprotein G is the attachment protein of respiratory syncytial virus. J Gen Virol (1987) 2.79
Dissociation between serum neutralizing and glycoprotein antibody responses of infants and children who received inactivated respiratory syncytial virus vaccine. J Clin Microbiol (1986) 2.43
Immune and histopathological responses in animals vaccinated with recombinant vaccinia viruses that express individual genes of human respiratory syncytial virus. J Virol (1987) 2.41
A role for immune complexes in enhanced respiratory syncytial virus disease. J Exp Med (2002) 2.34
Antigenic relatedness between glycoproteins of human respiratory syncytial virus subgroups A and B: evaluation of the contributions of F and G glycoproteins to immunity. J Virol (1987) 2.26
CX3C chemokine mimicry by respiratory syncytial virus G glycoprotein. Nat Immunol (2001) 2.21
Antigenic structure, evolution and immunobiology of human respiratory syncytial virus attachment (G) protein. J Gen Virol (1997) 2.13
Respiratory syncytial virus (RSV) F, G, M2 (22K), and N proteins each induce resistance to RSV challenge, but resistance induced by M2 and N proteins is relatively short-lived. J Virol (1991) 2.05
Respiratory syncytial virus G and/or SH protein alters Th1 cytokines, natural killer cells, and neutrophils responding to pulmonary infection in BALB/c mice. J Virol (1999) 1.71
The membrane-associated and secreted forms of the respiratory syncytial virus attachment glycoprotein G are synthesized from alternative initiation codons. J Virol (1994) 1.52
Structure and cell surface maturation of the attachment glycoprotein of human respiratory syncytial virus in a cell line deficient in O glycosylation. J Virol (1989) 1.50
Antigenic structure of the human respiratory syncytial virus G glycoprotein and relevance of hypermutation events for the generation of antigenic variants. J Gen Virol (1997) 1.49
Safety and immunogenicity of respiratory syncytial virus purified fusion protein-2 vaccine in pregnant women. Vaccine (2003) 1.48
Respiratory syncytial virus G protein and G protein CX3C motif adversely affect CX3CR1+ T cell responses. J Immunol (2006) 1.45
Pathogenesis of respiratory syncytial virus infection. Viral Immunol (2004) 1.42
Respiratory syncytial virus G and/or SH glycoproteins modify CC and CXC chemokine mRNA expression in the BALB/c mouse. J Virol (2000) 1.39
Respiratory syncytial virus pneumonitis in immunocompromised adults: clinical features and outcome. Respiration (2005) 1.39
Analysis of linear epitopes recognised by the primary human antibody response to a variable region of the attachment (G) protein of respiratory syncytial virus. J Med Virol (1997) 1.37
The cysteine-rich region of respiratory syncytial virus attachment protein inhibits innate immunity elicited by the virus and endotoxin. Proc Natl Acad Sci U S A (2005) 1.36
Further characterization of the soluble form of the G glycoprotein of respiratory syncytial virus. J Virol (1988) 1.26
Vaccination to induce antibodies blocking the CX3C-CX3CR1 interaction of respiratory syncytial virus G protein reduces pulmonary inflammation and virus replication in mice. J Virol (2009) 1.23
Therapeutic monoclonal antibody treatment targeting respiratory syncytial virus (RSV) G protein mediates viral clearance and reduces the pathogenesis of RSV infection in BALB/c mice. J Infect Dis (2009) 1.22
Respiratory syncytial virus immunobiology and pathogenesis. Virology (2002) 1.20
The G glycoprotein of respiratory syncytial virus depresses respiratory rates through the CX3C motif and substance P. J Virol (2003) 1.20
Progress in the development of respiratory syncytial virus and parainfluenza virus vaccines. Clin Infect Dis (2003) 1.20
Evaluation of the antibody specificities of human convalescent-phase sera against the attachment (G) protein of human respiratory syncytial virus: influence of strain variation and carbohydrate side chains. J Med Virol (2000) 1.17
The future of respiratory syncytial virus vaccine development. Pediatr Infect Dis J (2004) 1.17
Respiratory syncytial virus (RSV) vaccines--two steps back for one leap forward. J Clin Virol (2008) 1.17
Serious respiratory tract disease caused by respiratory syncytial virus: prospects for improved therapy and effective immunization. Pediatrics (1992) 1.15
Immunology of viral respiratory tract infection in infancy. Paediatr Respir Rev (2003) 1.14
Induction of protective immunity in rodents by vaccination with a prokaryotically expressed recombinant fusion protein containing a respiratory syncytial virus G protein fragment. Virology (1997) 1.14
Appearance of a soluble form of the G protein of respiratory syncytial virus in fluids of infected cells. J Gen Virol (1987) 1.13
The G protein of human respiratory syncytial virus: significance of carbohydrate side-chains and the C-terminal end to its antigenicity. J Gen Virol (1991) 1.12
Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in the institutionalized elderly. Vaccine (1997) 1.09
Treatment with respiratory syncytial virus G glycoprotein monoclonal antibody or F(ab')2 components mediates reduced pulmonary inflammation in mice. J Gen Virol (2009) 1.07
Respiratory syncytial virus deficient in soluble G protein induced an increased proinflammatory response in human lung epithelial cells. Virology (2004) 1.07
Host cell effect upon glycosylation and antigenicity of human respiratory syncytial virus G glycoprotein. Virology (1996) 1.06
Group-specific serum antibody responses in children with primary and recurrent respiratory syncytial virus infections. J Infect Dis (1991) 1.06
Safety and immunogenicity of a novel recombinant subunit respiratory syncytial virus vaccine (BBG2Na) in healthy young adults. J Infect Dis (2001) 1.06
Anti-G protein antibody responses to respiratory syncytial virus infection or vaccination are associated with inhibition of G protein CX3C-CX3CR1 binding and leukocyte chemotaxis. J Infect Dis (2004) 1.04
Safety and immunogenicity of a purified F protein respiratory syncytial virus (PFP-2) vaccine in seropositive children with bronchopulmonary dysplasia. J Infect Dis (1998) 1.04
T280M variation of the CX3C receptor gene is associated with increased risk for severe respiratory syncytial virus bronchiolitis. Pediatr Infect Dis J (2006) 1.02
Respiratory syncytial virus (RSV) infects neuronal cells and processes that innervate the lung by a process involving RSV G protein. J Virol (2006) 1.00
Respiratory syncytial virus F and G proteins induce interleukin 1alpha, CC, and CXC chemokine responses by normal human bronchoepithelial cells. J Infect Dis (2010) 0.99
Evaluation of BBG2Na in infant macaques: specific immune responses after vaccination and RSV challenge. Vaccine (2004) 0.92
Structural homology of the central conserved region of the attachment protein G of respiratory syncytial virus with the fourth subdomain of 55-kDa tumor necrosis factor receptor. Virology (1998) 0.91
Advances in respiratory syncytial virus vaccine development. Curr Opin Investig Drugs (2004) 0.91
Immunogenicity of purified F glycoprotein of respiratory syncytial virus: clinical and immune responses to subsequent natural infection in children. J Infect Dis (1993) 0.88
Protective immunity against respiratory syncytial virus in early life after murine maternal or neonatal vaccination with the recombinant G fusion protein BBG2Na. J Infect Dis (1997) 0.88
Humoral response to the central unglycosylated region of the respiratory syncytial virus attachment protein. Vaccine (2010) 0.84
The C-terminal third of human respiratory syncytial virus attachment (G) protein is partially resistant to protease digestion and is glycosylated in a cell-type-specific manner. J Gen Virol (2000) 0.81
Peptides as tools and drugs for immunotherapies. J Pept Sci (2007) 0.81
Gain-of-function experiments on H7N9. Science (2013) 3.67
Avian flu: Gain-of-function experiments on H7N9. Nature (2013) 2.32
Pause on avian flu transmission research. Science (2012) 2.24
Respiratory syncytial virus activates innate immunity through Toll-like receptor 2. J Virol (2008) 1.80
Counting single native biomolecules and intact viruses with color-coded nanoparticles. Anal Chem (2006) 1.64
RNA interference-mediated silencing of the respiratory syncytial virus nucleocapsid defines a potent antiviral strategy. Antimicrob Agents Chemother (2009) 1.60
Rapid and sensitive detection of respiratory virus molecular signatures using a silver nanorod array SERS substrate. Nano Lett (2006) 1.58
Human metapneumovirus persists in BALB/c mice despite the presence of neutralizing antibodies. J Virol (2004) 1.49
Respiratory syncytial virus G protein and G protein CX3C motif adversely affect CX3CR1+ T cell responses. J Immunol (2006) 1.45
Human Metapneumovirus: lessons learned over the first decade. Clin Microbiol Rev (2011) 1.38
Vaccination to induce antibodies blocking the CX3C-CX3CR1 interaction of respiratory syncytial virus G protein reduces pulmonary inflammation and virus replication in mice. J Virol (2009) 1.23
Therapeutic monoclonal antibody treatment targeting respiratory syncytial virus (RSV) G protein mediates viral clearance and reduces the pathogenesis of RSV infection in BALB/c mice. J Infect Dis (2009) 1.22
Comparison of the receptor binding properties of contemporary swine isolates and early human pandemic H1N1 isolates (Novel 2009 H1N1). Virology (2011) 1.22
The G glycoprotein of respiratory syncytial virus depresses respiratory rates through the CX3C motif and substance P. J Virol (2003) 1.20
The host response and molecular pathogenesis associated with respiratory syncytial virus infection. Future Microbiol (2009) 1.15
Rabies virus expressing dendritic cell-activating molecules enhances the innate and adaptive immune response to vaccination. J Virol (2010) 1.15
Potent high-affinity antibodies for treatment and prophylaxis of respiratory syncytial virus derived from B cells of infected patients. J Immunol (2009) 1.14
The immune response to human metapneumovirus is associated with aberrant immunity and impaired virus clearance in BALB/c mice. J Virol (2005) 1.09
Transmission studies resume for avian flu. Science (2013) 1.07
Respiratory syncytial virus proteins modulate suppressors of cytokine signaling 1 and 3 and the type I interferon response to infection by a toll-like receptor pathway. Viral Immunol (2009) 1.07
Treatment with respiratory syncytial virus G glycoprotein monoclonal antibody or F(ab')2 components mediates reduced pulmonary inflammation in mice. J Gen Virol (2009) 1.07
Comparative pathology in ferrets infected with H1N1 influenza A viruses isolated from different hosts. J Virol (2011) 1.05
Anti-G protein antibody responses to respiratory syncytial virus infection or vaccination are associated with inhibition of G protein CX3C-CX3CR1 binding and leukocyte chemotaxis. J Infect Dis (2004) 1.04
Replication and pathogenesis associated with H5N1, H5N2, and H5N3 low-pathogenic avian influenza virus infection in chickens and ducks. Arch Virol (2009) 1.02
An in vitro model of the leukocyte interactions associated with granuloma formation in Mycobacterium tuberculosis infection. Immunol Cell Biol (2007) 1.02
Respiratory syncytial virus modifies microRNAs regulating host genes that affect virus replication. J Gen Virol (2012) 1.01
Avian influenza viruses infect primary human bronchial epithelial cells unconstrained by sialic acid α2,3 residues. PLoS One (2011) 1.01
Respiratory syncytial virus (RSV) infects neuronal cells and processes that innervate the lung by a process involving RSV G protein. J Virol (2006) 1.00
Respiratory syncytial virus F and G proteins induce interleukin 1alpha, CC, and CXC chemokine responses by normal human bronchoepithelial cells. J Infect Dis (2010) 0.99
Monoclonal antibodies to SARS-associated coronavirus (SARS-CoV): identification of neutralizing and antibodies reactive to S, N, M and E viral proteins. J Virol Methods (2005) 0.99
Detection and differentiation of foodborne pathogenic bacteria in mung bean sprouts using field deployable label-free SERS devices. Analyst (2013) 0.98
MicroRNA regulation of human protease genes essential for influenza virus replication. PLoS One (2012) 0.96
A respiratory syncytial virus (RSV) anti-G protein F(ab')2 monoclonal antibody suppresses mucous production and breathing effort in RSV rA2-line19F-infected BALB/c mice. J Virol (2013) 0.95
Neutralizing anti-F glycoprotein and anti-substance P antibody treatment effectively reduces infection and inflammation associated with respiratory syncytial virus infection. J Virol (2002) 0.95
Induction and role of indoleamine 2,3 dioxygenase in mouse models of influenza a virus infection. PLoS One (2013) 0.94
Host gene targets for novel influenza therapies elucidated by high-throughput RNA interference screens. FASEB J (2012) 0.93
Label-free SERS detection of microRNA based on affinity for an unmodified silver nanorod array substrate. Chem Commun (Camb) (2010) 0.92
One-step assay for detecting influenza virus using dynamic light scattering and gold nanoparticles. Analyst (2011) 0.91
Identification of Host Kinase Genes Required for Influenza Virus Replication and the Regulatory Role of MicroRNAs. PLoS One (2013) 0.91
Quantitative surface-enhanced Raman spectroscopy based analysis of microRNA mixtures. Appl Spectrosc (2009) 0.90
The brume surrounding respiratory syncytial virus persistence. Am J Respir Crit Care Med (2004) 0.90
siRNA Genome Screening Approaches to Therapeutic Drug Repositioning. Pharmaceuticals (Basel) (2013) 0.89
Detection of Mycoplasma pneumoniae in simulated and true clinical throat swab specimens by nanorod array-surface-enhanced Raman spectroscopy. PLoS One (2010) 0.89
Rapid and sensitive detection of rotavirus molecular signatures using surface enhanced Raman spectroscopy. PLoS One (2010) 0.88
Inhibition of indoleamine 2,3-dioxygenase enhances the T-cell response to influenza virus infection. J Gen Virol (2013) 0.87
Nanoparticle vaccines encompassing the respiratory syncytial virus (RSV) G protein CX3C chemokine motif induce robust immunity protecting from challenge and disease. PLoS One (2013) 0.87
Detection and differentiation of avian mycoplasmas by surface-enhanced Raman spectroscopy based on a silver nanorod array. Appl Environ Microbiol (2011) 0.87
Serological cross-reactivity of members of the Metapneumovirus genus. Virus Res (2004) 0.87
Identification of individual genotypes of measles virus using surface enhanced Raman spectroscopy. Analyst (2010) 0.86
Targeting organic anion transporter 3 with probenecid as a novel anti-influenza a virus strategy. Antimicrob Agents Chemother (2012) 0.86
Bat cells from Pteropus alecto are susceptible to influenza A virus infection and reassortment. Influenza Other Respir Viruses (2013) 0.85
Aerosol inoculation with a sub-lethal influenza virus leads to exacerbated morbidity and pulmonary disease pathogenesis. Viral Immunol (2011) 0.85
Perspective on the host response to human metapneumovirus infection: what can we learn from respiratory syncytial virus infections? Microbes Infect (2005) 0.85
Real-time detection of virus particles and viral protein expression with two-color nanoparticle probes. J Virol (2005) 0.85
CD40 ligand (CD154) improves the durability of respiratory syncytial virus DNA vaccination in BALB/c mice. Vaccine (2003) 0.84
Therapeutic targeting of respiratory syncytial virus G-protein. Immunotherapy (2010) 0.84
Serum mannose-binding lectin levels are linked with respiratory syncytial virus (RSV) disease. J Clin Immunol (2007) 0.83
Adenovirus 36, adiposity, and bone strength in late-adolescent females. J Bone Miner Res (2013) 0.83
Antiviral responses by Swine primary bronchoepithelial cells are limited compared to human bronchoepithelial cells following influenza virus infection. PLoS One (2013) 0.82
Passage of low-pathogenic avian influenza (LPAI) viruses mediates rapid genetic adaptation of a wild-bird isolate in poultry. Arch Virol (2011) 0.82
Pulmonary delivery of respiratory syncytial virus DNA vaccines using macroaggregated albumin particles. Vaccine (2004) 0.81
Human respiratory syncytial virus non-structural protein NS1 modifies miR-24 expression via transforming growth factor-β. J Gen Virol (2015) 0.81
Combination therapy using monoclonal antibodies against respiratory syncytial virus (RSV) G glycoprotein protects from RSV disease in BALB/c mice. PLoS One (2012) 0.80
Indoleamine 2,3-dioxygenase (IDO) activity during the primary immune response to influenza infection modifies the memory T cell response to influenza challenge. Viral Immunol (2014) 0.80
RNA interference inhibits respiratory syncytial virus replication and disease pathogenesis without inhibiting priming of the memory immune response. J Virol (2008) 0.79
Aerosol vaccination induces robust protective immunity to homologous and heterologous influenza infection in mice. Vaccine (2011) 0.79
Label-free detection of micro-RNA hybridization using surface-enhanced Raman spectroscopy and least-squares analysis. J Am Chem Soc (2012) 0.79
Flexible and mechanical strain resistant large area SERS active substrates. Nanoscale (2012) 0.79
Targeting cell division cycle 25 homolog B to regulate influenza virus replication. J Virol (2013) 0.79
Visible-Light-Activated Bactericidal Functions of Carbon "Quantum" Dots. ACS Appl Mater Interfaces (2016) 0.79
Molecular and cellular mechanisms in the viral exacerbation of asthma. Microbes Infect (2008) 0.79
Human metapneumovirus establishes persistent infection in the lungs of mice and is reactivated by glucocorticoid treatment. J Virol (2009) 0.78
Advances in and the potential of vaccines for respiratory syncytial virus. Expert Rev Respir Med (2013) 0.78
Nebulized live-attenuated influenza vaccine provides protection in ferrets at a reduced dose. Vaccine (2011) 0.78
Identification of virulence determinants in influenza viruses. Anal Chem (2014) 0.77
Surveillance of feral cats for influenza A virus in north central Florida. Influenza Other Respir Viruses (2011) 0.77
Subsisting H1N1 influenza memory responses are insufficient to protect from pandemic H1N1 influenza challenge in C57BL/6 mice. J Gen Virol (2013) 0.77
A novel influenza virus hemagglutinin-respiratory syncytial virus (RSV) fusion protein subunit vaccine against influenza and RSV. J Virol (2013) 0.75